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Op18 is a 19 kDa cytosolic phosphoprotein that has been studied
independently in various cellular systems under different names
(e.g. p19, 19K, p18, prosolin and metablastin) (Doye et al, 1989;
Schubart et al, 1989; Zhu et al, 1989; Cooper et al, 1990; Gullberg
et al, 1990). The protein is conserved in vertebrates and expressed
in most tissues (Sobel, 1991). High expression of Op18 has been
observed in a number of human malignancies, for example acute
leukaemias, lymphomas, neuroblastomas and prostatic adenocar-
cinomas (Hanash et al, 1988; Hailat et al, 1990; Ghosh et al, 1993;
Roos et al, 1993, Luo et al, 1994; Friedrich et al, 1995). The signi-
ficance of tumour-specific up-regulation of Op18 is indicated by
experiments employing antisense inhibition of Op18 expression,
which shows that high levels of the protein may be necessary to
maintain the transformed phenotype in leukaemic cells (Jeha et al,
1996). In a recent report, Op18 was found to be overexpressed in a
subset of human breast carcinomas (Bièche et al, 1998). In this
study, the authors evaluated Op18 mainly at the mRNA level, but a
reasonable agreement with protein expression level was reported,
as measured by Western blot and immunohistochemistry. How-
ever, no significant correlations were observed between Op18
expression and established clinicopathologic parameters (Bièche
et al, 1998).
Op18 has been shown to regulate microtubule dynamics both in
vitro and in vivo (Belmont and Mitchison, 1996; Marklund et al,
1996). Unphosphorylated Op18 destabilizes microtubules both
in vivo and in vitro and binds to soluble ab-tubulin dimers,
while phosphorylation switches off both of these activities. No
interaction has so far been observed between Op18 and micro-
tubules. The mechanism by which Op18 mediates destabilization
of microtubules is currently controversial, but two distinct models
have been proposed involving either sequestering of tubulin
dimers or by specific catastrophe promotion, i.e. a switch from
growing to shrinking microtubules (reviewed by Cassimeris,
1999; McNally, 1999).
Op18 is phosphorylated on four serine residues (Ser16, Ser25,
Ser38 and Ser63) in intact cells by a wide range of extracellular
effectors and during mitosis (Labdon et al, 1992; Beretta et al,
1993; Leighton et al, 1993; Marklund et al, 1993a; 1993b; 1994;
Brattsand et al, 1994; Luo et al, 1994). Ser 16 and Ser63 are phos-
phorylated by protein kinase A, Ser16 by the Ca2+/calmodulin-
dependent kinase IV/Gr and Ser25 by members of the
mitogen-activated protein kinase family (MAP/ERK) while Ser25
and Ser38 are targets for phosphorylation by cyclin-dependent
kinases (reviewed by Lawler, 1998). Progression through mitosis
and formation of the mitotic spindle requires multisite phosphory-
lation on all four serine residues (Marklund et al, 1996; Larsson
et al, 1997). Op18 is implicated in microtubule regulation in
response to signal transduction events during interphase of the cell
cycle (Melander Gradin et al, 1997; 1998). Taken together, this
indicates a central role of Op18 in microtubule regulation.
The success of microtubule-directed chemotherapeutics such as
paclitaxel in cancer treatment and the abundant expression of
Op18 in breast cancer, warrants further analysis of the micro-
tubule-regulating protein Op18. The present study was initiated to
evaluate Op18 expression in relation to other clinicopathologic
characteristics in a larger panel of breast tumours. The results
show that Op18 expression correlates with several established
prognostic factors and that up-regulated expression is not
restricted to any specific subgroup of breast carcinoma.
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Summary Oncoprotein 18/stathmin (Op18) is a conserved cytosolic phosphoprotein that regulates microtubule dynamics. The microtubule
destabilizing activity is regulated by phosphorylation, mediated by both growth factor stimulated- and cell-cycle regulating kinases. The
protein is highly expressed in a variety of human malignancies. In human breast carcinoma, Op18 has previously been shown to be
up-regulated in a subset of the tumours, however, no correlation with clinicopathologic characteristics has been reported so far. In the present
study we have examined Op18 protein expression by quantitative Western blot analysis in a panel of 151 semi-consecutive breast carcinoma
samples. Op18 levels were negatively correlated with oestrogen receptor (OR) expression and positively correlated with a high fraction of
aneuploid cells, proliferation measured by proliferating cell nuclear antigen (PCNA) expression, tumour size and histopathologic grade. Taken
together, and in contrast to what has been previously reported, the present study shows that high Op18 expression correlates with general
predictive factors and is not restricted to a specific sub-group of breast carcinoma. © 2000 Cancer Research Campaign
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Patient data
The study included 151 women (median age 60 years; range
33–89). From all consecutive samples sent for OR analysis during
the first 7 months of 1996 in the northern health care region of
Sweden (197 totally), samples with a DNA content exceeding
62 mg were included in the study. Clinicopathologic characteristics
of the patients (Table 1) were determined in clinical routine.
Histopathologic grade was based on the recommendations by
Elston and Ellis (1991). The number of patients for whom data
were available varied among the different prognostic factors
studied. The study has been approved in the ethical committee,
Medical faculty, Umeå University.
Tumour tissue preparation
During primary surgery and after pathologic examination, repre-
sentative tumour tissue was cut out and sent frozen for ER
analyses. Tumour samples were stored frozen in liquid nitrogen
until analysed. Frozen tumour tissue was homogenized in a
microdish membrator (Braun, Melsungen, Germany) and
suspended in ice-cold buffer (10 mM Tris pH 7.4; 1.5 mM EDTA;
10 mM Na2MoO4; 1 mM monothioglycerol). Supernatants
(centrifugation 20 000 ´ g, 4°C, 10 min) were used for ER
analyses in clinical routine. The pelleted fractions were analysed
for DNA according to Burton (1968). The remaining portion of the
supernatant, not consumed in the receptor analyses, was frozen at
–70°C and the Western blot analyses were performed on this
archive material. A volume of supernatant corresponding
6.25–16.25 mg of DNA was precipitated in 66% acetone
overnight, –20°C. After centrifugation (16 000 ´ g for 15 min,
4°C), the protein pellet was dried under vacuum and resuspended
in 25–65 ml of loading buffer (135 mM Tris pH 6.8, 2.5% SDS,
10% glycerol, 10% beta-2-mercaptoethanole and bromphenol
blue) and heated for 2 min at 95°C. 20 ml of sample, corresponding
to 5 mg of DNA, was loaded onto a gel.
Protein standards and control samples
Purified recombinant Op18 with a protein concentration measured
by amino acid analysis was serial diluted in six steps in load-
ing buffer to generate a standard curve (range 1.5–49 ng per lane).
5 ng and 25 ng of Op18 per lane were used as control samples on
all filters containing patient samples. Triton X-100 lysates of the
cell line K562 was used as a standard curve, serially diluted in
five steps from 50 mg of total protein per lane, for arbitrary
quantification of PCNA.
SDS-PAGE and Western blot
20 ml of patient samples, protein standards or control samples were
loaded on 10–20% gradient SDS-PAGE gels and run on BioRad
Protean II xi for approximately 400 mAh until blue front had
passed through the gels (run time 5–16 h, running buffer: 2.5 mM
Tris; 0.2 mM glycine; 0.1% SDS). Electroelution in a Trans-blot
cell (plate electrodes, BioRad) to pre-wetted nitrocellulose filters
(Hybond ECL, Amersham) in buffer (20 mM Tris; 150 mM
glycine; 20% methanol; 0.01% SDS) for 4 h at 200 mA, 4°C.
Filters were washed 3 ´ 5 min in phosphate buffered saline (PBS),
stained for 15 s (50% methanol; 0.05% Coomassie blue) to
visualize protein pattern and molecular weight standards (LMW
calibration kit, Pharmacia), destained for 2 min (50% methanol;
10% acetic acid) and washed for 2 ´ 5 min in PBS. Filters were
dried overnight at room temperature. Strips corresponding to
Op18 (19 kD), triose phosphate isomerase (28 kD) and PCNA
(34 kD) were cut from filters and blocked in blocking buffer (5%
non-fat dried milk; 0.03% antifoam in PBS) for 5 h at room
temperature. For detection of Op18, strips were incubated with
anti Op18 rabbit antiserum (1/100) in blocking buffer. PCNA was
detected by the monoclonal antibody PC10 (DACO) 2 mg ml–1
in 15% foetal calf serum (FCS); 150 mM NaCl; 2.5 mM EDTA;
50 mM Tris pH 7.5; 0.02% NaN3. Antibody incubations were
carried out overnight at 4°C on a rocking table in sealed plastic
bags with 3.5 ml antibody solution per strip. Filters were then
washed for 2 min in TBS pH 7.5 (20 mM Tris pH 7.5; 137 mM
NaCl), 3 ´ 2 min in TBS-T pH 7.5 (0.1% Tween-20 in TBS) and
2 ´ 2 min in TBS pH 7.5. After primary antibody incubations and
washing, strips were incubated with 125I-protein A in 20% FCS;
150 mM NaCl; 2.5 mM EDTA; 50 mM Tris pH 8.8; 0.02% NaN3
for 30 min at room temperature. Filters were then washed 2 ´ 2
min in TBS pH 8.0, 5 ´ 2 min in TBS-T pH 8.0 and 3 ´ 2 min in
TBS pH 8.0. Filters were dried at room temperature for 3 h,
exposed on BioRad SI screens and analysed on BioRad phospho-
imager GS-525 Molecular Imager System. Exposure time was for
2–20 h (depending on antibody) to allow use of the dynamic range
of the screen without saturation. Immunoreactive bands on the
digital image were marked with rectangles of the same size.
Counts within the rectangle (volume counts ´ mm2) were used for
calculation of concentrations based on the standard curve within
312 G Brattsand
British Journal of Cancer (2000)  83(3), 311–318 © 2000 Cancer Research Campaign
Table 1 Clinicopathologic characteristics of the patients
Variable No of patients
Total patients (n) 151
Histologic type
Ductal invasive 72
Lobular invasive 5
Others 4
Not analysed 70
Tumour size
T1 (≤ 20 mm) 42
T2 (> 20 mm) 31
Not analysed 78
Histopathologic grade
I1 2
II 35
III 31
Not analysed 73
Node status
Node negative 50
Node positive 20
Not analysed 81
OR status
OR + (³ 0.1 fmol mg–1 DNA) 106
OR – (< 0.1 fmol mg–1 DNA) 45
Ploidy
Normoploid 14
Aneuploid 52
Not analysed 85
S-phase fraction
≤ 8% 44
> 8% 14
Not analysed 93each series. Op18 concentrations were recalculated as ng mg–1
DNA.
OR and progesterone receptor (PgR) analysis
OR and PgR content was determined by an enzyme immunoassay
(Abbott Lab, IL, USA). Receptor concentration was expressed as
fmol mg–1 DNA. Tumours with a value < 0.1 fmol mg–1 DNA were
considered receptor-negative and those with a value ³ 0.1 as
receptor-positive.
S-phase fraction, DNA ploidy and fraction of aneuploid
cells
Cell suspensions were prepared from frozen tissue and used for
DNA histogram analyses. DNA staining was done according to
Vindelov et al (1983) and analyses were performed on a FACScan
instrument (Becton Dickinson, CA, USA). S-phase fraction and
DNA index was calculated by Cellfit software (Becton Dickinson)
in RFIT model, when possible, or calculated manually. DNA
histograms were classified as diploid near diploid when only one
G0/G1 peak was detected at DNA index 1.0, and as aneuploid when
additional peaks were identified. The fraction of aneuploid cells, in
the samples classified as aneuploid, was estimated based on
comparison of the aneuploid G0/G1 peak and the diploid G0/G1
peak.
Cell lines
Breast cancer cell lines obtained from American Type Culture
Collection (ATCC) were grown in RPMI 1640 medium supple-
mented with 10% FCS and antibiotics. Cells were harvested with
trypsin, frozen and processed as the tumour samples.
Statistical analyses
Association between Op18 levels and established predictive
factors was evaluated by the Mann–Whitney rank test, with Op18
as continuous variable. Cut-offs for the group dividing variables
were according to guidelines of the North Swedish Breast Cancer
Group. Comparison of PCNA level, the fraction of aneuploid cells,
DNA index and Op18 were evaluated by the Mann–Whitney rank
test with Op18 as group-dividing variable with a cut-off value of
0.6 ng Op18 mg–1 DNA. The level of significance for rejecting the
null hypothesis of zero effect was taken to be P = 0.05. All calcu-
lations were performed in SPSS version 9.0 (SPSS, IL, USA).
RESULTS
Op18 expression in tumour samples
151 tumour specimens from breast cancer patients were analysed
for Op18 expression. This panel of specimens contained samples
from patients with primary, unilateral stage I–III disease and also
in a few cases samples came from patients with actual or previ-
ously diagnosed cancer in the same or opposite breast and/or stage
IV disease. Clinicopathologic characteristics of the patients are
outlined in Table 1. Determination of Op18 mass concentrations,
expressed as ng mg–1 of DNA, were performed by Western blot and
quantified by phosphoimager as described in the Materials and
Methods section. Representative exposures of Western blots are
shown in Figure 1. The Op18 antiserum used detected a single
band only at 19 kD in the patient material as described earlier
(Brattsand et al, 1993). An extra band with slightly higher molec-
ular weight is seen in the Op18 control samples in Figure 1. This is
because an epitope-tagged recombinant Op18 protein with eight
extra amino acids was mixed with native Op18 in the samples used
as control. This band is without significance for the current study
and is not included in the quantitative measurements.
The Op18 expression varied considerably among the tumours
as seen in Figure 1 and the frequency distribution histogram in
Figure 2. Some tumours exhibited at least 10–20 times higher
Op18 concentration than others. Western blot of the glycolytic
enzyme triose-phosphate isomerase (TPI) was used as an internal
control and showed only minor variations (Figure 1). Only a faint
TPI band is seen in the K562 lysate in Figure 1 since the total
loaded protein amount is less than in the patient samples. It is
evident from Figure 2 that the frequency distribution of Op18 is
considerably asymmetric. The limit of quantitative measurement
was defined as 0.3 ng mg–1 DNA since this corresponds to an Op18
standard concentration giving rise to a signal higher than the mean
background signal plus three times the standard deviation (SD) of
the background signal. However, the concentrations have been
extrapolated at even lower values. The Western blot method used
to quantify Op18 protein levels was validated and showed a total
coefficient of variation (CV) of around 30% for Op18 standards
and patient samples (data not shown). This means that two quanti-
tative measurements are separate with 95% confidence when they
Op18 in breast cancer 313
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Figure 1 Representative Western blots of protein extracts from seven
breast cancer samples, three standard levels of recombinant Op18 protein
and the cell line K562 using antibodies to PCNA, TPI and Op18 (an extra
band with slightly higher molecular weight is seen in the Op18 blot in the
Op18 control samples, this is due to inclusion of a tagged variant of
recombinant Op18 and is without significance for the current study)
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Figure 2 Frequency distribution histogram of the Op18 level in 151 breast
cancer samples. The left vertical axis represents number of cases in each
concentration interval and the right vertical axis represents percent of total
number of cases. The limit of quantitative measurement was defined as
0.3 ng of Op18 per mg of DNA and the cut-off level used in statistical analysis
was 0.6 ng of Op18 per mg of DNAdiffer by a factor of around two (Sadler et al, 1992). As seen in
Figure 2, the median Op18 expression was below 0.3 ng mg–1
DNA, i.e. below the limit of quantitative measurement. By using a
cut-off that is twice the limit of quantitative measurement, i.e.
0.6 ng mg–1 DNA, it is possible to separate a group of tumours that
show higher and more varied Op18 expression than the rest. This
group represents 22% of the samples and is defined as a group of
tumours with up-regulated Op18 expression. This cut-off was used
in the subsequent statistical analysis.
Relationship between Op18 and other parameters
Associations between Op18 levels and other accessible biological
and clinical parameters are shown in Tables 2 and 3 for the 151
patients. A significant relationship exists between loss of OR
expression and Op18 level (P = 0.001). This relationship was also
significant in Person’s c2 test when a cut-off Op18 of 0.6 ng mg–1
DNA was used (P = 0.002). The inverse relationship between
Op18 and OR expression is illustrated in Figure 3. A similar nega-
tive correlation was observed between Op18 and progesterone-
receptor expression (Table 2). A significant positive correlation
was seen between tumour size and Op18 levels, as well as between
histopathologic grade and Op18 levels (Table 2). Expression of
Op18 was significantly correlated to PCNA expression, arbitrarily
quantified by Western blot as described in the Materials and
Methods section (Table 3). The level of Op18 was also compared
with the fraction of aneuploid cells in the tumour samples
harbouring aneuploid populations (Table 3 and Figure 4). It is
evident that the tumour samples showing the highest Op18 levels
also harbour a high fraction of aneuploid cells. No correlations
were seen between Op18 levels and node status, ploidy status,
DNA index (Table 2 and 3) or age (not shown).
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Table 2 Rank test with Op18 as continuous variable
Variable na Mean rank P-valuec
Op18b Asymp.sig. (2-tailed)
OR expression
OR + (³ 0.1 fmol mg–1 DNA) 106 68.4 0.001
OR – (< 0.1 fmol mg–1 DNA) 45 94.0
PgR expression
PgR + (³ 0.1 fmol mg–1 DNA) 96 67.4 0.001
PgR – (< 0.1 fmol mg–1 DNA) 55 91.0
Size
T1 (≤ 20 mm) 42 32.0 0.020
T2 (> 20 mm) 31 43.7
Histopathologic grade
I + II 47 35.0 0.030
III 31 46.3
S-phase fraction
≤ 8% 44 27.4 0.092
> 8% 14 36.1
Node status
Negative 50 35.1 0.800
Positive 20 36.5
Ploidy
Normoploid 14 34.0 0.912
Aneuploid 52 33.4
aNumber of patients with accessible data for the group in the variable, bmean rank of Op18 expression for the group in
the variable, cMann–Whitney U test.
Table 3 Rank test with Op18 as group dividing variable
Variable na Mean rank of variableb P-valuec
Asymp.sig. (2-tailed)
PCNA
Op18 ≤ 0.6 ng mg–1 DNA 118 67.6 <0.001
Op18 > 0.6 ng mg–1 DNA 33 106.1
Fraction of aneuploid cells
Op18 ≤ 0.6 ng mg–1 DNA 40 22.7 0.003
Op18 > 0.6 ng mg–1 DNA 11 37.9
DNA index
Op18 ≤ 0.6 ng mg–1 DNA 39 26.1 0.956
Op18 > 0.6 ng mg–1 DNA 12 25.8
aNumber of patients with accessible data for the two groups, bmean rank of the variable PCNA expression, fraction of
aneuploid cells (%) and DNA index, respectively for the two groups, cMann–Whitney U test.Op18 in breast cancer 315
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Figure 3 Op18 concentrations vs OR concentrations in 151 breast cancer samples
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Figure 4 Op18 concentrations vs the fraction of aneuploid cells (expressed as %) in 51 breast cancer samples harbouring aneuploid populationsOp18 expression in breast cancer cell lines
To determine if up-regulated Op18 expression is a constitutive
feature of OR-negative breast cancer cells, five cell lines of breast
cancer origin were investigated for Op18 expression. The cell lines
MDA-MB 468 and MDA-MB 231 (Cailleau et al, 1978) were
confirmed to be OR-negative and the cell lines MCF-7, T-47D1
and CAMA-1 (Soule et al, 1973; Fogh et al, 1977; Keydar et al,
1979) were confirmed to be OR-positive (Table 4). The mean of
Op18’s quadruple determination in the five cell lines are shown in
Table 4. The OR-negative cell lines showed the highest Op18
expression, indicating that up-regulated Op18 expression is
present even after long-term in vitro culture of OR-negative breast
cancer cells. It is apparent from Figure 2 and Table 4 that the
tumour samples showing the highest Op18 expression have similar
levels to the ones seen in cell lines. Calculation of Op18 expres-
sion per total protein amount did not alter the interrelationship
between the cell lines (data not shown).
DISCUSSION
The quantitative Western blot data in this study are based on
measurements of DNA content in the samples. Protein content has
been measured in 127 of the 151 patient samples and correlates
with DNA content (correlation coefficient (r) of 0.66). In average,
based on linear regression, 1 mg of DNA corresponds to 10 mg of
total protein (data not shown). Quantification per DNA may be
more specific than per protein, due to the influence of extracellular
and blood proteins in the biopsies. Samples with a high DNA
index (i.e. polyploid) did not show any consistent bias towards
lower relative protein amount (data not shown). Recalculation of
the quantitative measurements per protein did not induce any
gross alterations in the observed correlation with clinicopathologic
parameters.
Control samples from normal breast tissue have not been avail-
able for this study. Aneuploid cells in a tumour sample can, for
good reasons, be regarded as malignant. The observation that a
high level of Op18 is seen in samples with a high fraction of aneu-
ploid cells (Figure 4) shows that Op18 is mainly expressed by the
malignant cells in the samples and the level of Op18 measured by
Western blot reflects both the expression of individual tumour
cells and the fraction of tumour cells in the samples. In an earlier
study by Bièche et al (1998), control samples showed low Op18
expression on the mRNA level and infiltrating lymphocytes were
shown to express weak or no Op18 immunoreactivity upon
immunohistochemical stainings. Taken together, these lines of
evidence show that a high Op18 level reflects specific expression
by tumour cells and that at least some breast carcinoma cells have
an up-regulated Op18 expression. We can define a group of breast
carcinomas representing 22% of the cases, that with statistical
confidence show up-regulated Op18 expression. In the study by
Bièche et al (1998), 15 of 50 breast carcinoma samples were
defined to overexpress Op18 on the mRNA level. In that study the
Op18 protein concentration range (seven samples) was broader
than we found, however comparison is difficult since no mass unit
was used in the earlier study.
High Op18 levels correlate with loss of OR (Figure 3). In agree-
ment with the finding in patient material, the OR-negative cell
lines MDA-MB 468 and MDA-MB 231 show higher Op18 levels
than the OR-positive cell lines CAMA-1, T47-D1 and MCF 7
(Table 4). Several other factors are also known to correlate with
loss of OR, for example proliferation (Fechter et al, 1988;
Sigurdsson et al, 1990; Meyer and Province, 1994), overexpres-
sion of cycline E (Nielsen et al, 1996), and mutations in the p53
gene (Caleffi et al, 1994).
To evaluate the proliferative status in the tumour samples, PCNA
was quantified by Western blot. Levels of Op18 correlate with
PCNA levels (Table 3) which indicates an association with prolifer-
ation in breast carcinoma. The fraction of cells in S-phase shows a
weak correlation with Op18 levels, although this correlation was
not statistically significant (Table 2). Whether Op18 expression in
general is linked to proliferation seems to depend on the
cell/tissue/tumour system studied (Brattsand et al, 1993; Koppel et
al, 1993; Roos et al, 1993; Nylander et al, 1995; Balogh et al, 1996).
It has been speculated that defective mitotic spindle check-
points and aberrant regulation of centrosomes are involved in
chromosomal genetic instability (reviewed for example by
Lengauer et al, 1998, Zimmerman et al, 1999). An obvious ques-
tion is of course whether Op18 could be involved in such
processes considering its regulatory effects on microtubule
dynamics. However, Op18 levels do not show any correlation with
the ploidy status of the tumours (Table 2), and this argues against
such an involvement. Op18 levels do not show any correlation
with lymph node engagement (Table 2) and this argues against
Op18 being involved in the metastatic process.
The reason for the up-regulated expression of Op18 in tumour
cells has remained elusive. However, recent findings suggest the
Op18 gene to be transcriptionally repressed by a p53/histone
deacetylase complex (Ahn et al, 1999; Murphy et al, 1999). The
up-regulated Op18 expression in tumour cells may thus, at least in
part, reflect a defective p53/histone deacetylase signalling func-
tion. This is in line with the observation that Op18 expression
correlates with loss of OR expression, which in turn correlates
with mutations in the p53 gene (Caleffi et al, 1994).
To conclude, in contrast to what has previously been reported,
the present study shows that high Op18 expression correlates well
with general prognostic factors and is not restricted to a specific
subgroup of breast carcinomas. Further investigations on the
usefulness of Op18 as a prognostic marker for disease-free
survival and overall survival in breast carcinomas are in process.
The association between Op18 expression and malignancy in
breast carcinoma and other tumour types makes the protein of
further interest to study in the context of tumourogenesis involving
cytoskeletal alterations, p53 signalling, apoptosis, and response to
chemotherapy, considering its role in microtubule regulation. For
example, Op18 partially antagonizes the microtubule stabilizing
effect of paclitaxel in the cell line K562 (Marklund et al, 1996),
and therefore it cannot be excluded that Op18 may be a resistance
factor for microtubule-directed chemotherapy.
Interestingly, the expression of microtubule-associated protein 4
(MAP4), a protein also transrepressed on transcriptional level by
p53(Murphy et al, 1999), affects the sensitivity to antimicrotubule
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Table 4 Op18 expression in breast cancer cell lines
Cell line OR (pmol mg–1 DNA) Op18 (ng mg–1 DNA)
MDA-MB 468 0.0 7.6
MDA-MB 231 0.0 4.7
CAMA-1 0.2 3.8
T-47D1 0.3 3.2
MCF-7 0.2 1.2drugs (Zhang et al, 1998; 1999). It has been speculated that micro-
tubule regulation is an important downstream event during p53-
dependent induction of apoptosis (Ahn et al, 1999; Murphy et al,
1999). Such a pathway, influenced by p53-mediated repression of
both Op18 and MAP4, may be of importance for treatment of
cancer patients with microtubule-directed chemotherapy.
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Note added in proof
After the submission of this report, a study concerning Op18 in
breast cancer has been published (Curmi et al, Br J Cancer 82:
142–150). In this study Op18 is measured on mRNA level by
competitive RT-PCR and correlates to loss of steroid receptors and
histopathologic grade, which agrees with the conclusions of the
present study.
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